Newsletter The Women’s Health Activist® is a bimonthly publication of the National Women’s Health Network. We’d like to hear from you. Please e-mail questions or comments to email@example.com.
By Elizabeth Miller, MD, PhD
By Jill Battalen, Director of Individual Giving
By Margaret Conway, Lydia Stuckey and Kirsten Moore
By D'Laura Brumfield
By Charlea T. Massion, MD & Adriane Fugh-Berman, MD
In mid-July, a Food and Drug Administration (FDA) advisory committee voted to keep the diabetes drug Avandia (rosiglitazone) on the market, while simultaneously acknowledging not only that the drug increases the risk of heart attacks, but also that there are many other, safer medications available — including Actos (pioglitazone), a close sibling of Avandia made by a competing manufacturer.
By Amy Allina, NWHN Policy Director
By Natieka Samuels
In the last NWHN Board of Directors elections, all three incumbents were re-elected: Bindiya Patel, Laura Kaplan and Susan Wood. In addition, three members will join the board in June: Priscilla Huang, Charlea Massion, and Zipatly Mendoza. Learn more about these excellent women in their candidate’s statements, below:
By Nekose Wills
By Cynthia Pearson
By Gina Smith
Review: The Push To Prescribe — Women and Canadian Drug Policy Edited by Anne Rochon Ford and Diane Saibil
By Ann Pappert
In 1992, when I first moved back to the U.S. after living in Canada for more than 20 years, I would stare in amazement at the endless parade of prescription drug commercials that appeared nightly across my TV screen. Direct-to-consumer ads for prescription drugs weren’t permitted in Canada. But here in the States, the ads were everywhere.
By Tracey Stelzer Hyams, JD, MPH
June Board Meeting
The NWHN board of directors will meet next in Washington, DC on June 12 & 13. NWHN members are welcome to join us for parts of the weekend. If you are interested in attending, please contact the office for more information at 202.682.2640.
By Cynthia Pearson
By Charlea T. Massion, MD, and Adriane Fugh-Berman, MD